Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10758503-B2
Publication Date
2020-09-01
Expiration Date
Abstract
NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.
Core Innovation
Not explicitly described in patent.
Claims Coverage
Independent claims identified: 2 (clm-00001 and clm-00017). The inventive features concentrate on an intravenous-suitable container holding a specific pharmaceutical composition including glibenclamide or a pharmaceutically acceptable salt thereof and mannitol, with additional definition for sterile water or dosage/formulation constraints.
Intravenous container composition with glibenclamide and mannitol
A container containing a composition suitable for intravenous administration, the composition comprising glibenclamide or a pharmaceutically acceptable salt thereof, mannitol, and a pharmaceutically acceptable carrier.
Intravenous composition of about 1 mg glibenclamide with sterile water and mannitol
A container containing a composition suitable for intravenous administration, wherein the composition comprises about 1 mg glibenclamide or a pharmaceutically acceptable salt thereof, mannitol, and sterile water.
Across the independent claims, the patent’s claim coverage centers on a container holding an intravenous-suitable pharmaceutical composition comprising glibenclamide or a pharmaceutically acceptable salt thereof and mannitol, with one independent claim specifying sterile water and a particular about-1 mg glibenclamide amount.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?